Acadian Asset Management LLC, a prominent investment management firm, has recently increased its position in shares of Organogenesis Holdings Inc. The increase amounted to 18.4% during the first quarter of this year, as reported in their most recent Form 13F filing with the Securities and Exchange Commission (SEC). Acadian Asset Management now owns a total of 1,408,713 shares of Organogenesis stock, after acquiring an additional 219,098 shares over the course of the quarter. This represents approximately 1.07% ownership of Organogenesis with a value of $2,999,000 based on their SEC filing.
Organogenesis Holdings Inc., listed on the NASDAQ exchange under the ticker symbol ORGO, is a regenerative medicine company that focuses on developing innovative solutions for the advanced wound care market and the surgical and sports medicine sectors within the United States. Their portfolio includes a range of advanced wound care products designed to facilitate healing and improve patient outcomes.
In their most recent quarterly earnings report released on August 9th, Organogenesis reported earnings per share (EPS) of $0.04 for the quarter. This exceeded the consensus estimate by $0.02 per share. Additionally, the company generated revenue of $117.32 million during this period, surpassing analyst estimates of $115.25 million. These positive financial results reflect Organogenesis’ strong performance in delivering value to its shareholders.
The net margin for Organogenesis stood at 2.20%, indicating that they were able to effectively manage costs and generate profit during the quarter. Furthermore, they achieved a return on equity (ROE) of 5.65%, highlighting their ability to utilize shareholders’ investments efficiently.
Looking ahead, equities analysts anticipate that Organogenesis Holdings Inc.’s EPS for the current fiscal year will be approximately -0.01 cents per share.
Organogenesis’ core focus lies in developing and commercializing advanced wound care products. These include Affinity, an amniotic membrane wound covering that preserves viable cells, growth factors/cytokines, and extracellular matrix (ECM) proteins; Novachor, a chorion membrane wound covering with similar preservation capabilities; Apligraf, a bioengineered living cell therapy that produces various cytokines and growth factors; Dermagraft, a bioengineered product that generates human collagen, ECM proteins, and cytokines; NuShield, a wound covering that incorporates amnion and chorion membranes for added effectiveness; and PuraPly, an antimicrobial barrier offering conformability and fluid drainage.
Overall, Organogenesis Holdings Inc. continues to make significant strides in the regenerative medicine industry by developing innovative solutions for advanced wound care. With the support of investors like Acadian Asset Management LLC and their promising financial performance in recent earnings reports, Organogenesis is well positioned to drive growth and further enhance their contribution to the medical field.
Large Investors Increase Stake in Regenerative Medicine Company Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a leading regenerative medicine company, has recently seen changes in its ownership as several large investors made adjustments to their positions in the company. Ameritas Investment Partners Inc., for instance, raised its holdings in Organogenesis by a staggering 80.1% during the first quarter of this year. The firm now owns 5,386 shares of Organogenesis’ stock, valued at $41,000, after acquiring an additional 2,396 shares.
Point72 Hong Kong Ltd also increased its stake in Organogenesis by a significant margin. The company now holds 6,015 shares of Organogenesis’ stock valued at $29,000 after acquiring an additional 4,275 shares during the second quarter.
Similarly, Lazard Asset Management LLC expanded its holdings in Organogenesis by a whopping 3,808.2% during the first quarter. After buying an additional 8,873 shares, Lazard Asset Management now owns 9,106 shares with an estimated value of $69,000.
These investment moves indicate that institutional investors and hedge funds collectively own 39.48% of Organogenesis’ stock.
In addition to these substantial share acquisitions by major investors, Baird Financial Group Inc. acquired a new position in Organogenesis during the fourth quarter valued at approximately $29,000. ProShare Advisors LLC also acquired a new position in the same period valued at around $30,000.
Shares of ORGO opened at $2.80 on Friday. The fifty-day moving average stands at $3.43 while the two-hundred-day moving average is recorded at $2.95. Throughout the past year’s trading activity on the stock market, Organogenesis Holdings experienced a low of $1